4-chloromethyl-2-(2-furyl)oxazole | 202594-83-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-chloromethyl-2-(2-furyl)oxazole
• 英文别名: 4-chloromethyl-2-(furan-2-yl)oxazole；4-chloromethyl-2-(furan-2-yl)-1,3-oxazole；4-(chloromethyl)-2-(furan-2-yl)-1,3-oxazole
• CAS: 202594-83-0
• 化学式: C₈H₆ClNO₂
• 分子量: 183.594
• InChiKey: IPQVNELHJFCPMW-UHFFFAOYSA-N

物化性质

• 沸点：
  301.1±45.0 °C(Predicted)
• 密度：
  1.299±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-chloromethyl-2-(2-furyl)oxazole 、 香草醛 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 以91%的产率得到4-{[2-(furan-2-yl)-1,3-oxazol-4-yl]methoxy}-3-methoxybenzaldehyde
  参考文献：
  名称：

  FIVE-MEMBERED HETEROCYCLIC COMPOUNDS

  摘要：

  本发明提供了一种由以下式表示的化合物： 其中R1是可选择地取代的5-成员杂环基团；X、Y和V相同或不同，每个都是键，氧原子，硫原子等；Q是具有1到20个碳原子的二价碳氢基团；环A是一个芳香环，可选择地进一步具有1到3个取代基；Z是-(CH2)n-Z1-或-Z1-(CH2)n-（n是0到8的整数，Z1是键，氧原子，硫原子等）；环B是一个含氮杂环，可选择地进一步具有1到3个取代基；W是键或具有1到20个碳原子的二价碳氢基团；R2是氢原子，氰基，-PO(OR9)(OR10)（R9和R10相同或不同，每个是氢原子或可选择地取代的碳氢基团，R9和R10可选择地结合形成可选择地取代的环）等，或其盐，具有优越的减少脂肪组织重量的作用，降糖作用和降脂作用，并且作为预防或治疗肥胖症，糖尿病，高脂血症，糖耐量受损，高血压等的药剂是有用的。

  公开号：

  EP1541564A1
• 作为产物：
  描述：

  [2-(Furan-2-yl)-1,3-oxazol-4-yl]methanol 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 4-chloromethyl-2-(2-furyl)oxazole
  参考文献：
  名称：

  Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against MDR- and XDR-MTB

  摘要：

  A high-throughput screening effort on 45,000 compounds resulted in the discovery of a disubstituted oxazole as a new structural class inhibitor of Mycobacterium tuberculosis (Mtb). In order to improve the activity and investigate the SAR of this scaffold, a series of disubstituted azole analogues have been designed and synthesized. The newly synthesized compounds 1a-y were evaluated for their in vitro anti-TB activity versus replicating, multi-and extensive drug resistant Mtb strains. All the compounds, except 1o, 1p and 1q, showed potent anti-TB activity with MIC of 1-64 mg/L. The test of broad spectrum panel revealed that this series are specific to Mtb. The cytotoxicity assessment indicated that the compounds were not cytotoxic against HEK 293 cells. The compounds could have a novel mechanism to anti-Mtb as they can inhibit drug sensitive and drug resistant Mtb. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.09.072

文献信息

• Heterocyclic compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06211215B1

  公开（公告）日：2001-04-03

  Heterocyclic compounds represented by the general formula (I) wherein R stands for an optionally substituted aromatic heterocyclic group; X stands for oxygen atom, an optionally oxidated sulfur atom, —C(═O)— or —CH(OH)—; Y stands for CH or N; m denotes an integer of 0 to 10: n denotes an integer of 1 to 5: cyclic group  stands for an optionally substituted aromatic azole group; and ring A is optionally further substituted, or salts thereof. The compound (I) possesses action of inhibiting tyrosine kinase and useful as antitumor agents.

  通式（I）代表的杂环化合物，其中R代表一个可选择取代的芳香杂环基团；X代表氧原子，一个可选择氧化的硫原子，—C(═O)—或—CH(OH)—；Y代表CH或N；m表示0到10的整数；n表示1到5的整数；环状基团代表一个可选择取代的芳香唑基团；环A可以是可选择进一步取代的，或其盐。化合物（I）具有抑制酪氨酸激酶的作用，并可用作抗肿瘤剂。
• [EN] COMPOUNDS USEFUL AS INHIBITORS OF SODIUM-CALCIUM EXCHANGER (NCX)<br/>[FR] COMPOSÉS UTILES EN TANT QU'ÉCHANGEUR SODIUM-CALCIUM (NCX)
  申请人：ORION CORP

  公开号：WO2019175464A1

  公开（公告）日：2019-09-19

  The present invention related to compounds of formula (I) wherein R1, R2, ring A and ring Bare as defined in the claims. The compounds are potent inhibitors of the sodium-calcium exchanger (NCX) and are useful in the treatment or prevention of various clinical conditions in which intracellular calcium homeostasis is disturbed, including ischemic diseases and arrhythmias. In particular, the compounds of formula (I) are useful as inotropic agents in the treatment and 10 prevention of conditions in which inotropic support is required to maintain a sufficient level of blood supply, for example, in the treatment of heart failure or in the treatment of patients undergoing surgery.

  本发明涉及公式（I）的化合物，其中R1、R2、环A和环B的定义如权利要求所述。这些化合物是钠钙交换体（NCX）的有效抑制剂，可用于治疗或预防各种临床病症，其中细胞内钙平衡受到干扰，包括缺血性疾病和心律失常。特别地，公式（I）的化合物在治疗和预防需要肌力支持以维持足够血液供应水平的病症方面是有用的，例如在治疗心力衰竭或在治疗接受手术的患者方面。
• Five-membered heterocyclic compounds
  申请人：Momose Yu

  公开号：US20060135578A1

  公开（公告）日：2006-06-22

  The present invention provides a compound represented by the formula: wherein R 1 is an optionally substituted 5-membered heterocyclic group; X, Y and V are the same or different and each is a bond, an oxygen atom, a sulfur atom and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is —(CH 2 ) n -Z 1 - or -Z 1 -(CH 2 ) n — (n is an integer of 0 to 8, Z 1 is a bond, an oxygen atom, a sulfur atom and the like); ring B is a nitrogen-containing heterocycle optionally further having 1 to 3 substituents; W is a bond or a divalent hydrocarbon group having 1 to 20 carbon atoms; R 2 is a hydrogen atom, a cyano group, —PO(OR 9 )(OR 10 ) (R 9 and R 10 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, and R 9 and R 10 are optionally bonded to form an optionally substituted ring) and the like, or a salt thereof, which has a superior adipose tissue weight decreasing action, a hypoglycemic action and a hypolipidemic action, and which is useful as an agent for the prophylaxis or treatment of obesity, diabetes mellitus, hyperlipidemia, impaired glucose tolerance, hypertension and the like.

  本发明提供一种化合物，其化学式表示为：其中，R1为可选取的取代的5-成员杂环基；X、Y和V相同或不同，每个都是键，氧原子，硫原子等；Q为具有1到20个碳原子的二价碳氢基团；环A为芳香环，可选地进一步具有1到3个取代基；Z为—(CH2)n-Z1-或-Z1-(CH2)n—（n为0到8的整数，Z1为键，氧原子，硫原子等）；环B为含氮杂环，可选地进一步具有1到3个取代基；W为键或具有1到20个碳原子的二价碳氢基团；R2为氢原子，氰基，—PO(OR9)(OR10)（R9和R10相同或不同，每个都是氢原子或可选取的取代的碳氢基团，R9和R10可选择性地结合形成可选取的取代环）等，或其盐，具有优异的减轻脂肪组织重量、降血糖和降血脂作用，可用作预防或治疗肥胖症、糖尿病、高脂血症、糖耐量受损、高血压等的药剂。
• Synthesis of tetracyclic 4 <i>H</i> ‐benzo[5,6]chromeno[3,4‐ <i>d</i> ]oxazoles via palladium‐catalyzed intramolecular direct heteroarylation
  作者：Sujeet Kumar、Km Kajol、Prakash Nayak、Amit Kumar、Chintakunta Ramesh

  DOI：10.1002/asia.202201151

  日期：2023.2

  An efficient method is disclosed for the synthesis of various tetracyclic 4H-benzo[5,6]chromeno[3,4-d]oxazoles from oxazole tethered β-naphthols via intramolecular direct heteroarylation by employing a palladium catalyst. Furthermore, photophysical properties of the resulting molecules were evaluated by using UV/vis absorption and fluorescence spectroscopy.

  公开了一种使用钯催化剂通过分子内直接杂芳基化从恶唑系链β-萘酚合成各种四环 4 H-苯并[5,6]苯并[3,4- d ]恶唑的有效方法。此外，通过使用 UV/vis 吸收和荧光光谱评估所得分子的光物理性质。
• HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0912562A1

  公开（公告）日：1999-05-06